A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

被引：0
|
作者：
A H Ko
M A Tempero
Y-S Shan
W-C Su
Y-L Lin
E Dito
A Ong
Y-W Wang
C G Yeh
L-T Chen
机构：
[1] Comprehensive Cancer Center,Division of Hematology/Oncology
[2] University of California,Department of Surgery
[3] San Francisco,Department of Internal Medicine
[4] National Cheng Kung University Hospital,Department of Oncology
[5] National Cheng Kung University Hospital,Department of Internal Medicine and Cancer Center
[6] National Taiwan University Hospital,undefined
[7] PharmaEngine,undefined
[8] Inc.,undefined
[9] National Institute of Cancer Research,undefined
[10] National Health Research Institutes,undefined
[11] Kaohsiung Medical University Hospital,undefined
[12] Kaohsiung Medical University,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
Irinotecan sucrosofate; liposome; pancreatic cancer; second-line; gemcitabine-refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：920 / 925
页数：5
相关论文
共 50 条
  • [21] Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
    Ioka, T.
    Komatsu, Y.
    Mizuno, N.
    Tsuji, A.
    Ohkawa, S.
    Tanaka, M.
    Iguchi, H.
    Ishiguro, A.
    Kitano, M.
    Satoh, T.
    Yamaguchi, T.
    Takeda, K.
    Kida, M.
    Eguchi, K.
    Ito, T.
    Munakata, M.
    Itoi, T.
    Furuse, J.
    Hamada, C.
    Sakata, Y.
    BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 464 - 471
  • [22] Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
    Merz, Valeria
    Zecchetto, Camilla
    Santoro, Raffaela
    Simionato, Francesca
    Sabbadini, Fabio
    Mangiameli, Domenico
    Piro, Geny
    Cavaliere, Alessandro
    Deiana, Michela
    Valenti, Maria Teresa
    Bazan, Diana
    Fedele, Vita
    Lonardi, Sara
    Melisi, Davide
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4661 - 4669
  • [23] Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
    Kim, Yoon Jae
    Bang, Seungmin
    Park, Jeong Youp
    Park, Seung Woo
    Chung, Jae Bock
    Song, Si Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) : 529 - 533
  • [24] Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
    Yoon Jae Kim
    Seungmin Bang
    Jeong Youp Park
    Seung Woo Park
    Jae Bock Chung
    Si Young Song
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 529 - 533
  • [25] A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
    Pijnappel, Esther
    de Vos-Geelen, Judith
    Macarulla Mercade, Teresa
    Melisi, Davide
    Pfeiffer, Per
    Prager, Gerald W.
    Van Laarhoven, Hanneke W. M.
    Wilmink, Johanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] A phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer
    Miyata, E.
    Okuwaki, K.
    Imaizumi, H.
    Kida, M.
    Iwai, T.
    Yamauchi, H.
    Kaneko, T.
    Hasegawa, R.
    Adachi, K.
    Tadehara, M.
    Koizumi, W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer.
    Stathopoulos, GP
    Aravantinos, G
    Syrigos, K
    Kalbakis, K
    Karvounis, N
    Papakotoulas, P
    Boukovinas, J
    Potamianou, A
    Polyzos, A
    Christophilakis, CH
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [28] Effects of nanoliposomal irinotecan (nal-IRI;MM-398) ± 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
    Siveke, J. T.
    Cubillo, A.
    Blanc, J. -F
    Melisi, D.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L. -T
    Becker, C.
    Mamlouk, K.
    Belanger, B.
    Yang, Y.
    de Jong, F.
    Hubner, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 259 - 259
  • [29] Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer
    Mizuno, Nobumasa
    Yamao, Kenji
    Komatsu, Yoshito
    Munakata, Masaki
    Ishiguro, Atsushi
    Yamaguchi, Taketo
    Ohkawa, Shinichi
    Kida, Mitsuhiro
    Ioka, Tatsuya
    Takeda, Koji
    Kudo, Toshihiro
    Kitano, Masayuki
    Iguchi, Haruo
    Tsuji, Akihito
    Ito, Tetsuhide
    Tanaka, Masao
    Furuse, Junji
    Hamada, Chikuma
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [30] Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies
    Ma, W. W.
    Chung, I.
    Lang, I.
    Csoszi, T.
    Wenczl, M. W.
    Cubillo, A.
    Chen, J.
    Wong, M.
    Park, J. O.
    Kim, J. S.
    Rau, K. M.
    Melichar, B.
    Gallego, J.
    Smakal, M.
    Kim, J.
    Belanger, B.
    Bayever, E.
    Adiwijaya, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S458 - S458
12345